• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ENHANCE trial: Simvastatin and ezetimibe in familial hypercholesterolemia [Classics Series]

byLauren KoandAndrew Cheung, MD MBA
September 11, 2014
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with familial hypercholesterolemia, simvastatin and ezetimibe combination therapy does not result in significant differences in carotid artery thickness when compared to treatment with simvastatin alone.

2. Treatment with simvastatin and ezetimibe led to significantly greater reductions in LDL cholesterol, triglyceride, and C-reactive protein levels as compared to treatment with simvastatin alone.

3. There were no significant differences between the two groups in the rates of adverse events or drug discontinuation.

Original Date of Publication: April 3, 2008

Study Rundown: Ezetimibe is a cholesterol-absorption inhibitor that lowers plasma cholesterol by decreasing the amount of cholesterol absorption in the small intestine. This drug is sometimes used in combination with statins, and this combination has been shown to further reduce levels of low-density lipoprotein (LDL) when compared to statins alone. No prior large-scale randomized clinical trial had been conducted to assess the effect of adding ezetimibe to statins on atherosclerosis progression. In the ENHANCE trial, 720 patients with familial hypercholesterolemia were randomized to receive simvastatin with placebo or simvastatin with ezetimibe. After 24 months of therapy, there was no significant difference between the two groups in mean change in intima-media thickness of the carotid arteries (P=0.29). Nevertheless, patients that took combination therapy rather than simvastatin alone experienced greater reductions in LDL cholesterol, triglyceride, and C-reactive protein levels.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: This double-blinded randomized control trial was originally published in the NEJM in 2008. It was conducted at 18 centres in the United States, Canada, South Africa, Spain, Denmark, Norway, Sweden, and the Netherlands. Patients were eligible for the study if they were between 30-75 years of age and had been diagnosed with familial hypercholesterolemia by genotyping or World Health Organization diagnostic criteria. Exclusion criteria included having high-grade stenosis/occlusion of the carotid artery, a history of carotid endarterectomy/stenting, homozygous familial hypercholesterolemia, New York Heart Association class III or IV congestive heart failure, and cardiac arrhythmia. All patients underwent a screening phase, a single-blind 6-week placebo run-in period, and a double-blind study period lasting 24 months. The primary outcome was the mean change in intima-media thickness of the carotid arteries, as measured by ultrasonography of the carotid arteries.

RELATED REPORTS

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

Quick Take: Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older

2 Minute Medicine Rewind July 22, 2019

A total of 720 patients with familial hypercholesteremia were randomized into two treatment groups: 1) simvastatin 80 mg daily with placebo or 2) simvastatin 80 mg daily and ezetimibe 10 mg daily. In the simvastain-only group, the mean change in thickness was 0.0058±0.0037 mm, while it was 0.0111±0.0038 mm in the simvastatin-ezetimibe group, an insignificant difference (P=0.29). Patients in the simvastatin-ezetimibe group experienced a 16.5% greater reduction in LDL levels compared with the simvastatin-only group (P<0.01). Patients in the combination group also experienced significantly greater reductions in triglyceride and C-reactive protein levels, when compared with simvastatin alone (P<0.01). There were no significant differences between the two groups in the rates of adverse events and medication discontinuation.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: ezetimibe (Zetia)simvastatin
Previous Post

Hemorrhage during gastrectomy linked to increased cancer recurrence

Next Post

Benzodiazepine use linked with Alzheimer’s disease

RelatedReports

Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Cardiology

Quick Take: Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older

July 27, 2019
Placebo formulation impacts effectiveness of pain control in osteoarthritis
Weekly Rewinds

2 Minute Medicine Rewind July 22, 2019

August 17, 2019
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Modelling study suggests that statins may be overprescribed

December 9, 2018
Next Post
Dementia prevalence declining in the UK

Benzodiazepine use linked with Alzheimer's disease

Ultrasound, flow reserve guided coronary interventions provide minimal benefit

Coronary angioplasty safe and effective at facilities without on-site cardiothoracic surgery

Preterm birth associated with elevated plasma insulin levels

GLP-1 agonist and basal insulin an effective anti-diabetic regimen

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
  • Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
  • Extracorporeal CPR and conventional CPR similarly improve cardiac arrest survival
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options